Vanesa Nozal

发表

Protein kinase inhibitors for amyotrophic lateral sclerosis therapy

Ana Martínez, V. Palomo, Elisa Rojas-Prats, 2020, British journal of pharmacology.

Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles

Ana Martínez, D. Perez, Loreto Martínez-González, 2021, Pharmaceutics.

COVID-19: Drug Targets and Potential Treatments

N. Campillo, Tiziana Ginex, David Ramírez, 2020, Journal of medicinal chemistry.

Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles †

Ana Martínez, D. Perez, Elisa Rojas-Prats, 2021, International journal of molecular sciences.

Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods

Ana Martínez, N. Campillo, Tiziana Ginex, 2020, bioRxiv.

From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein‐Templated Synthesis

C. Pérez, Ana Martínez, V. Palomo, 2021, Angewandte Chemie.

Improved linkage design for the discovery of multitarget ligands as powerful drugs for Alzheimer’s disease

C. Pérez, Ana Martínez, V. Palomo, 2019 .

TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.

S. Knapp, Ana Martínez, A. Chaikuad, 2022, Journal of medicinal chemistry.

TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis.

Ana Martínez, V. Palomo, Siranjeevi Nagaraj, 2019, ACS chemical neuroscience.

Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases.

Ana Martínez, Vanesa Nozal, 2019, European journal of medicinal chemistry.